Skip to main content
SpringerLink
Log in

Disposition of paclitaxel (Taxol®) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin®)

  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

Monoclonal antibodies are capable of modulating drug metabolising enzymes resulting in unexpected plasma concentrations of a drug when given concomitantly. Therefore plasma concentration of paclitaxel (PTX) and its metabolites has been monitored in 10 patients with advanced breast cancer during treatment with PTX alone or combined with trastuzumab (TMAB, paired cross over design). Compared to the MONO regimen PTX peak plasma concentrations were about 25 % lower in the TMAB schedule: cmax=3294 ± 1174 ng/ml (MONO: 4368 ± 1887 ng/ml). TMAB also caused lower peak plasma concentration of the main metabolite 6-hydroxy PTX (248 ± 89 ng/ml) compared to the MONO schedule (194 ± 82 ng/ml). Cmax of the minor metabolites was distinctly below 100 ng/ml and consequently differed negligible in both schedules. The similar apparent formation rate of the metabolites in both schedules (range from 30 to 50 min) as well as identical tmax values (range 170–190 min) suggested that TMAB had no influence on PTX metabolism. In accordance to plasma concentrations, AUClast of PTX was lower in the MONO schedule (733 ± 197 μg/ml*min, AUClast=669 ± 248 μg/ml*min for TMAB) but without significance. In summary no indices for an altered plasma disposition of PTX and its metabolites could be found when TMAB was given concomitantly.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Winer E.P., Burstein H.J. (2001): New combinations with Herceptin in metastatic breast cancer. Oncology 61, 50–57

    Article  CAS  PubMed  Google Scholar 

  2. Merlin J.L., Barberi-Heyob M., Bachmann N. (2002): In-vitro comparative evaluation of trastuzumab (Hercerptin®) combined with paclitaxel (Taxol®) or docetaxel (Taxotere®) in HER2-expressing human breast cancer cell lines. Ann. Oncol. 13, 1743–48

    Article  PubMed  Google Scholar 

  3. Hortobagy G.N. (2000): Developments in chemotherapy of breast cancer. Cancer 88,3073–3079

    Article  Google Scholar 

  4. Esteva F.J., Valero V., Pusztai L., Boehnke-Michaud L., Buzdar A.U., Hortobagy G.N. (2001): Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6, 133–146

    Article  CAS  PubMed  Google Scholar 

  5. Shak S. (1999): Overview of the trastuzumab (Herceptin®) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin. Oncol. 26, 71–77

    CAS  PubMed  Google Scholar 

  6. Weiner L.M. (1999): An overview of monoclonal antibody therapy in cancer. Semin. Oncol. 26, 41–50

    CAS  PubMed  Google Scholar 

  7. Goldenberg M.M. (1999): Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin. Ther. 21, 309–318

    Article  CAS  PubMed  Google Scholar 

  8. Hortobagy G.N. (2001): Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin. Oncol. 28, 43–47

    Google Scholar 

  9. Seidman A.D., Fornier M.N. Esteva F.J. (2001): Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J. Clin. Oncol. 19, 2587–95

    CAS  PubMed  Google Scholar 

  10. O’Shaughnessy J. (2003): Gemcitabine and trastuzumab in metastatic breast cancer. Semin. Oncol. 30, 22–26

    PubMed  Google Scholar 

  11. Ligibel J.A., Winer E.P. (2002): Trastuzumab / chemotherapy combinations in metastatic breast cancer. Sem. Oncol. 29, 38–43

    CAS  Google Scholar 

  12. Gori S., Colozza M., Mosconi A.M., Franceschi E., Basurto C, Sidoni A., Rulli A., Bisacci C, De Angelis V., Crino L. Tonato M. (2004): Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane pretreated patients with HER2-overexpressing metastatic breast cancer. Br. J. Cancer 90, 36–40

    Article  CAS  PubMed  Google Scholar 

  13. Cresteil T., Monsarrat B., Alvinerie P. (1994): Taxol metabolism by human hepatic microsomes: identification of cytochrome P450 isoenzymes involved in its biotransformation. Cancer Res. 54, 386–392

    CAS  PubMed  Google Scholar 

  14. Karlsson M.O., Molnar V., Freijs A., Nygren P., Bergh J. Rolf L.A. (1999): Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab. Disp. 27, 1220–23

    CAS  Google Scholar 

  15. Kearns C.M. (1997): Pharmacokinetics of Taxanes. Pharmacotherapy 17, 105–109

    Google Scholar 

  16. Gelboin H.V., Krausz K.W., Shou M., Gonzalez F.J. Yang T.J. (1997): A monoclonal antibody inhibitory to human P450 2D6: Paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism. Pharmacogenetics 7, 469–477

    Article  CAS  PubMed  Google Scholar 

  17. Krausz K.W., Goldfarb I., Buters J.T.M., Yang T.J., Gonzalez F.J., Gelboin H.V. (2001): Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8,2C9 and 2C19. Drug Metab. Dispos. 29, 1410–1423

    CAS  PubMed  Google Scholar 

  18. Schmider J., Greenblatt D.J., von Moltke L.L., Harmatz J.S., Duan S.X., Karsov D., Shader R.I. (1996): Characterization of six in-virro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450 directed antibodies. Pharmacology 52, 125–134

    Article  CAS  PubMed  Google Scholar 

  19. Shu L., Hollenberg P.F. (1996): Identification of the cytochrome P450 isoenzymes involved in the metabolism of N-nitrosodipropyl-, N-nitrosodibutyl- and N-nitroso-N-butyl-N-propylamine. Carcinogenesis 17, 839–848

    Article  CAS  PubMed  Google Scholar 

  20. Czejka M.J., Schueller J., Schnait H., Springer B. Eder I. (2003): Clinical pharmacokinetics and metabolism of paclitaxel after 3-hour infusion: comparison of two preparations. J. Oncol. Pharm. Pract. 9, 127–136

    Article  Google Scholar 

  21. Harris K.A., Washington C.B., Lieberman G., Lu J.F., Mass R., Bruno R. (2002): A population pharmacokinetic model for trastuzumab (Herceptin®) and implications for clinical dosing. Proc. ASCO, Abstract No. 488

  22. Gelmon K., Arnold A., Verma S., Ayoub J.P., Hemmings F., Layland-Jones B. (2001): Pharmacokinetics and safety of trastuzumab (Herceptin®) when administered every three weeks to women with metastatic breast cancer. Proc. ASCO, Abstract No. 271

  23. Strehlau J., Pape L., Offner G., Nashan B., Ehrich J.H, (2000): Interleukin-2 receptor antibody induced alterations of Ciclosporin dose requirements in paediatric transplant recipients. Lancet 356, 1327–132

    Article  CAS  PubMed  Google Scholar 

  24. Leyland-Jones B., Gelmon K., Ayoub J.P., Arnold A., Verma S., Dias R., Grahamani P. (2003): Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J. Clin. Oncol. 21, 3965–71

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dep. of Clinical Pharmacy and Diagnostics, University of Vienna, Althanstrasse 14, 1090, Vienna, Austria

    A. Furtlehner, I. Jarisch & M. Czejka

  2. Dep. of Oncology and Internal Medicine, Hospital Rudolfstiftung, Vienna, Austria

    J. Schueller & E. Ostermann

  3. Austrian Society of Applied Pharmacokinetics, Vienna, Austria

    J. Schueller & M. Czejka

Authors
  1. A. Furtlehner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Schueller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I. Jarisch
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Ostermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Czejka
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Furtlehner, A., Schueller, J., Jarisch, I. et al. Disposition of paclitaxel (Taxol®) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin®). European Journal of Drug Metabolism and Pharmacokinetics 30, 145–150 (2005). https://doi.org/10.1007/BF03190613

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03190613

Keywords

Search

Navigation